Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of August 2025, specifically detailing a share repurchase executed on August 7, 2025. The filing serves as a disclosure of a non-discretionary buyback agreement executed through Merrill Lynch International.
Key Financial Metrics and Transaction Details
The filing details a specific share repurchase transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow are not included in this specific document).
- Shares Purchased: 502,466 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,361.00 GBp; highest price paid was 1,385.50 GBp.
- Volume-Weighted Average Price (VWAP): 1,376.94 GBp.
- Trading Venue: London Stock Exchange (XLON). No purchases were made on CBOE Europe venues (CHIX or BATE) on this date.
- Program Status: Since the agreement commenced on June 4, 2025, the Company has purchased a total of 21,410,644 ordinary shares.
- Treasury Holdings: Following this purchase, GSK holds 239,545,027 ordinary shares in treasury.
- Shares in Issue: 4,075,843,458 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.88% of the total voting rights.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the buyback program. The filing confirms the ongoing execution of the non-discretionary agreement entered into on June 4, 2025. No other material changes to the company's financial position or operations are disclosed in this specific transaction report.
Guidance, Outlook, and Risks
The filing contains a standard cautionary statement regarding forward-looking statements. GSK notes that any projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as those described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and GSK's Q2 Results for 2025. No new guidance or specific outlook commentary is provided in this document.
Important Facts for Investors to Verify
- Verify the total remaining authorization under the buyback program to assess future capital return potential.
- Confirm the impact of the 5.88% treasury share holding on earnings per share (EPS) calculations and voting thresholds.
- Review the referenced 2024 Form 20-F and Q2 2025 results for the full context of risk factors mentioned in the cautionary statement.
- Monitor the execution of the non-discretionary agreement to ensure it aligns with the company's stated capital allocation strategy.